High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study
Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to tr...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1994 |
|---|
| Umfang: |
8 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Annals of hematology - 1955, 69(1994) vom: Apr., Seite 181-188 |
| Übergeordnetes Werk: |
volume:69 ; year:1994 ; month:04 ; pages:181-188 ; extent:8 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202974146 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202974146 | ||
| 003 | DE-627 | ||
| 005 | 20230506011249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1994 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202974146 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study |
| 264 | 1 | |c 1994 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Scherrer, R. |4 oth | |
| 700 | 1 | |a Bettelheim, P. |4 oth | |
| 700 | 1 | |a Geissler, K. |4 oth | |
| 700 | 1 | |a Jäger, U. |4 oth | |
| 700 | 1 | |a Knöbl, P. |4 oth | |
| 700 | 1 | |a Kyrle, P. A. |4 oth | |
| 700 | 1 | |a Laczika, K. |4 oth | |
| 700 | 1 | |a Mitterbauer, G. |4 oth | |
| 700 | 1 | |a Neumann, E. |4 oth | |
| 700 | 1 | |a Schneider, B. |4 oth | |
| 700 | 1 | |a Schwarzinger, I. |4 oth | |
| 700 | 1 | |a Lechner, K. |4 oth | |
| 773 | 0 | 8 | |i in |t Annals of hematology |d 1955 |g 69(1994) vom: Apr., Seite 181-188 |w (DE-627)NLEJ18898836X |w (DE-600)1458429-3 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:1994 |g month:04 |g pages:181-188 |g extent:8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF02215951 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 1994 |c 4 |h 181-188 |g 8 | ||
| matchkey_str |
article:14320584:1994----::ihfiayfhgramlietrlgalrtclotetetfdlaueypolsilu |
|---|---|
| hierarchy_sort_str |
1994 |
| publishDate |
1994 |
| allfields |
(DE-627)NLEJ202974146 DE-627 ger DE-627 rakwb eng High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study 1994 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. Springer Online Journal Archives 1860-2002 Scherrer, R. oth Bettelheim, P. oth Geissler, K. oth Jäger, U. oth Knöbl, P. oth Kyrle, P. A. oth Laczika, K. oth Mitterbauer, G. oth Neumann, E. oth Schneider, B. oth Schwarzinger, I. oth Lechner, K. oth in Annals of hematology 1955 69(1994) vom: Apr., Seite 181-188 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:69 year:1994 month:04 pages:181-188 extent:8 http://dx.doi.org/10.1007/BF02215951 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 69 1994 4 181-188 8 |
| spelling |
(DE-627)NLEJ202974146 DE-627 ger DE-627 rakwb eng High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study 1994 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. Springer Online Journal Archives 1860-2002 Scherrer, R. oth Bettelheim, P. oth Geissler, K. oth Jäger, U. oth Knöbl, P. oth Kyrle, P. A. oth Laczika, K. oth Mitterbauer, G. oth Neumann, E. oth Schneider, B. oth Schwarzinger, I. oth Lechner, K. oth in Annals of hematology 1955 69(1994) vom: Apr., Seite 181-188 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:69 year:1994 month:04 pages:181-188 extent:8 http://dx.doi.org/10.1007/BF02215951 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 69 1994 4 181-188 8 |
| allfields_unstemmed |
(DE-627)NLEJ202974146 DE-627 ger DE-627 rakwb eng High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study 1994 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. Springer Online Journal Archives 1860-2002 Scherrer, R. oth Bettelheim, P. oth Geissler, K. oth Jäger, U. oth Knöbl, P. oth Kyrle, P. A. oth Laczika, K. oth Mitterbauer, G. oth Neumann, E. oth Schneider, B. oth Schwarzinger, I. oth Lechner, K. oth in Annals of hematology 1955 69(1994) vom: Apr., Seite 181-188 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:69 year:1994 month:04 pages:181-188 extent:8 http://dx.doi.org/10.1007/BF02215951 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 69 1994 4 181-188 8 |
| allfieldsGer |
(DE-627)NLEJ202974146 DE-627 ger DE-627 rakwb eng High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study 1994 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. Springer Online Journal Archives 1860-2002 Scherrer, R. oth Bettelheim, P. oth Geissler, K. oth Jäger, U. oth Knöbl, P. oth Kyrle, P. A. oth Laczika, K. oth Mitterbauer, G. oth Neumann, E. oth Schneider, B. oth Schwarzinger, I. oth Lechner, K. oth in Annals of hematology 1955 69(1994) vom: Apr., Seite 181-188 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:69 year:1994 month:04 pages:181-188 extent:8 http://dx.doi.org/10.1007/BF02215951 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 69 1994 4 181-188 8 |
| allfieldsSound |
(DE-627)NLEJ202974146 DE-627 ger DE-627 rakwb eng High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study 1994 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. Springer Online Journal Archives 1860-2002 Scherrer, R. oth Bettelheim, P. oth Geissler, K. oth Jäger, U. oth Knöbl, P. oth Kyrle, P. A. oth Laczika, K. oth Mitterbauer, G. oth Neumann, E. oth Schneider, B. oth Schwarzinger, I. oth Lechner, K. oth in Annals of hematology 1955 69(1994) vom: Apr., Seite 181-188 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:69 year:1994 month:04 pages:181-188 extent:8 http://dx.doi.org/10.1007/BF02215951 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 69 1994 4 181-188 8 |
| language |
English |
| source |
in Annals of hematology 69(1994) vom: Apr., Seite 181-188 volume:69 year:1994 month:04 pages:181-188 extent:8 |
| sourceStr |
in Annals of hematology 69(1994) vom: Apr., Seite 181-188 volume:69 year:1994 month:04 pages:181-188 extent:8 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Annals of hematology |
| authorswithroles_txt_mv |
Scherrer, R. @@oth@@ Bettelheim, P. @@oth@@ Geissler, K. @@oth@@ Jäger, U. @@oth@@ Knöbl, P. @@oth@@ Kyrle, P. A. @@oth@@ Laczika, K. @@oth@@ Mitterbauer, G. @@oth@@ Neumann, E. @@oth@@ Schneider, B. @@oth@@ Schwarzinger, I. @@oth@@ Lechner, K. @@oth@@ |
| publishDateDaySort_date |
1994-04-01T00:00:00Z |
| hierarchy_top_id |
NLEJ18898836X |
| id |
NLEJ202974146 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202974146</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506011249.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202974146</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scherrer, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bettelheim, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Geissler, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jäger, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Knöbl, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kyrle, P. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laczika, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mitterbauer, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neumann, E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schneider, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schwarzinger, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lechner, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">69(1994) vom: Apr., Seite 181-188</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:69</subfield><subfield code="g">year:1994</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:181-188</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF02215951</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">69</subfield><subfield code="j">1994</subfield><subfield code="c">4</subfield><subfield code="h">181-188</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ18898836X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0584 |
| topic_title |
High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r s rs p b pb k g kg u j uj p k pk p a k pa pak k l kl g m gm e n en b s bs i s is k l kl |
| hierarchy_parent_title |
Annals of hematology |
| hierarchy_parent_id |
NLEJ18898836X |
| hierarchy_top_title |
Annals of hematology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ18898836X (DE-600)1458429-3 |
| title |
High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study |
| spellingShingle |
High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study |
| ctrlnum |
(DE-627)NLEJ202974146 |
| title_full |
High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study |
| journal |
Annals of hematology |
| journalStr |
Annals of hematology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1994 |
| contenttype_str_mv |
zzz |
| container_start_page |
181 |
| container_volume |
69 |
| physical |
8 |
| format_se |
Elektronische Aufsätze |
| title_sort |
high efficacy of the german multicenter all (gmall) protocol for treatment of adult acute lymphoblastic leukemia (all) — a single-institution study |
| title_auth |
High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study |
| abstract |
Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. |
| abstractGer |
Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. |
| abstract_unstemmed |
Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study |
| url |
http://dx.doi.org/10.1007/BF02215951 |
| remote_bool |
true |
| author2 |
Scherrer, R. Bettelheim, P. Geissler, K. Jäger, U. Knöbl, P. Kyrle, P. A. Laczika, K. Mitterbauer, G. Neumann, E. Schneider, B. Schwarzinger, I. Lechner, K. |
| author2Str |
Scherrer, R. Bettelheim, P. Geissler, K. Jäger, U. Knöbl, P. Kyrle, P. A. Laczika, K. Mitterbauer, G. Neumann, E. Schneider, B. Schwarzinger, I. Lechner, K. |
| ppnlink |
NLEJ18898836X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth |
| up_date |
2024-07-06T09:25:41.194Z |
| _version_ |
1803821190947536896 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202974146</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506011249.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202974146</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scherrer, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bettelheim, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Geissler, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jäger, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Knöbl, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kyrle, P. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laczika, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mitterbauer, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neumann, E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schneider, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schwarzinger, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lechner, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">69(1994) vom: Apr., Seite 181-188</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:69</subfield><subfield code="g">year:1994</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:181-188</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF02215951</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">69</subfield><subfield code="j">1994</subfield><subfield code="c">4</subfield><subfield code="h">181-188</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| score |
7.3989067 |